{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:12:11Z","timestamp":1779358331591,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"S9","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Menschen mit Diabetes mellitus k\u00f6nnen im allt\u00e4glichen Management durch Diabetestechnologie mittels automatisierter Insulinabgabesysteme (AID-Systeme) unterst\u00fctzt werden und dadurch das Hypoglyk\u00e4mierisiko reduzieren und die glyk\u00e4mische Kontrolle sowie die Lebensqualit\u00e4t verbessern. Aufgrund von unterschiedlichsten Barrieren in der AID-Verf\u00fcgbarkeit hat sich international die Nutzung von Open-source-AID-Systemen entwickelt. Diese Technologien bieten eine notwendige Alternative zu kommerziellen Produkten, insbesondere, wenn zugelassene Systeme unzug\u00e4nglich oder unzureichend auf die spezifischen Bed\u00fcrfnisse der Anwendenden angepasst sind. Open-source-Technologie zeichnet sich durch global freie Verf\u00fcgbarkeit von Codes im Internet aus, durchl\u00e4uft kein offizielles Zulassungsverfahren, und die Verwendung erfolgt daher auf eigene Verantwortung. In der klinischen Praxis f\u00fchren fehlende Expertise zu den unterschiedlichen Systemen und Bedenken vor juristischen Konsequenzen zu Konfliktsituationen f\u00fcr Behandler:innen und mitunter zur Ablehnung in der Betreuung von Menschen mit Diabetes mellitus, die Open-source-Technologie nutzen m\u00f6chten. Im vorliegenden Positionspapier sollen eine \u00dcbersicht zu vorhandener Evidenz sowie praktische Orientierungshilfen f\u00fcr medizinisches Fachpersonal geboten werden, um Unsicherheiten und Barrieren zu minimieren. Menschen mit Diabetes mellitus m\u00fcssen \u2013\u00a0unabh\u00e4ngig von der von ihnen gew\u00e4hlten Diabetestechnologie\u00a0\u2013 weiterhin in Schulung, Umgang und Management ihrer Erkrankung unterst\u00fctzt werden, auch wenn sie sich f\u00fcr die Verwendung eines Open-source-Systems entschieden haben. Medizinische Kontrollen der metabolischen Einstellung, akuter und chronischer Komplikationen sowie das Screening auf assoziierte Erkrankungen sind unabh\u00e4ngig vom gew\u00e4hlten AID-System notwendig und sollen durch multidisziplin\u00e4re Teams mit entsprechender Expertise erfolgen.<\/jats:p>","DOI":"10.1007\/s00508-024-02400-x","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T10:02:12Z","timestamp":1724839332000},"page":"467-477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Positionspapier: Open-source-Technologie in der Behandlung von Menschen mit Diabetes mellitus\u00a0\u2013 eine \u00f6sterreichische Perspektive","Position paper: Open-source technology in the treatment of people living with diabetes mellitus\u2014an Austrian perspective"],"prefix":"10.1007","volume":"136","author":[{"given":"Antonia-Therese","family":"Kietaibl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Sch\u00fctz-Fuhrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latife","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Fr\u00fchwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Rami-Merhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Fr\u00f6hlich-Reiterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine E.","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Tauschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Resl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"H\u00f6rtenhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Stechemesser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Winhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Zlamal-Fortunat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies","family":"Eichner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schelkshorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimund","family":"Weitgasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gersina","family":"Rega-Kaun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia K.","family":"Mader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"1","key":"2400_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00508-023-02165-9","volume":"135","author":"I Sch\u00fctz-Fuhrmann","year":"2023","unstructured":"Sch\u00fctz-Fuhrmann\u00a0I, Rami-Merhar\u00a0B, Fr\u00f6hlich-Reiterer\u00a0E, Hofer\u00a0SE, Tauschmann\u00a0M, Mader\u00a0JK, et\u00a0al. Diabetestechnologie (Update 2023). Wien Klin Wochenschr. 2023;135(1):53\u201361.","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"2400_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00508-023-02182-8","volume":"135","author":"M Lechleitner","year":"2023","unstructured":"Lechleitner\u00a0M, Kaser\u00a0S, Hoppichler\u00a0F, Roden\u00a0M, Weitgasser\u00a0R, Ludvik\u00a0B, et\u00a0al. Diagnostik und Therapie des Typ\u00a01 Diabetes mellitus (Update 2023). Wien Klin Wochenschr. 2023;135(1):98\u2013105.","journal-title":"Wien Klin Wochenschr"},{"issue":"Supplement_1","key":"2400_CR3","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc24-S006","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","unstructured":"American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes\u20142024. Diabetes Care. 2023;47(Supplement_1):S111\u2013S25.","journal-title":"Diabetes Care"},{"issue":"8","key":"2400_CR4","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/pedi.13455","volume":"23","author":"M De Bock","year":"2022","unstructured":"De Bock\u00a0M, Codner\u00a0E, Craig\u00a0ME, Huynh\u00a0T, Maahs\u00a0DM, Mahmud\u00a0FH, et\u00a0al. ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatr Diabetes. 2022;23(8):1270\u20136.","journal-title":"Pediatr Diabetes"},{"issue":"Supplement_1","key":"2400_CR5","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.2337\/dc24-S007","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","unstructured":"American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes\u20142024. Diabetes Care. 2023;47(Supplement_1):S126\u2013S44.","journal-title":"Diabetes Care"},{"issue":"9","key":"2400_CR6","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.2337\/dc23-0495","volume":"46","author":"KE Karakus","year":"2023","unstructured":"Karakus\u00a0KE, Akturk\u00a0HK, Alonso\u00a0GT, Snell-Bergeon\u00a0JK, Shah\u00a0VN. Association between diabetes technology use and glycemic outcomes in adults with type\u00a01 diabetes over a\u00a0decade. Diabetes Care. 2023;46(9):1646\u201351.","journal-title":"Diabetes Care"},{"issue":"361","key":"2400_CR7","doi-asserted-by":"publisher","first-page":"k1310","DOI":"10.1136\/bmj.k1310","volume":"18","author":"E Bekiari","year":"2018","unstructured":"Bekiari\u00a0E, Kitsios\u00a0K, Thabit\u00a0H, Tauschmann\u00a0M, Athanasiadou\u00a0E, Karagiannis\u00a0T, et\u00a0al. Artificial pancreas treatment for outpatients with type\u00a01 diabetes: systematic review and meta-analysis. BMJ. 2018;18(361):k1310.","journal-title":"BMJ"},{"issue":"3","key":"2400_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa2111673","volume":"386","author":"J Ware","year":"2022","unstructured":"Ware\u00a0J, Allen\u00a0JM, Boughton\u00a0CK, Wilinska\u00a0ME, Hartnell\u00a0S, Thankamony\u00a0A, et\u00a0al. Randomized trial of closed-loop control in very young children with type\u00a01 diabetes. N\u00a0Engl J Med. 2022;386(3):209\u201319.","journal-title":"N Engl J Med"},{"issue":"5","key":"2400_CR9","doi-asserted-by":"publisher","first-page":"e14741","DOI":"10.1111\/dme.14741","volume":"39","author":"C Knoll","year":"2022","unstructured":"Knoll\u00a0C, Peacock\u00a0S, W\u00e4ldchen\u00a0M, Cooper\u00a0D, Aulakh\u00a0SK, Raile\u00a0K, et\u00a0al. Real-world evidence on clinical outcomes of people with type\u00a01 diabetes using open-source and commercial automated insulin dosing systems: a\u00a0systematic review. Diabet Med. 2022;39(5):e14741.","journal-title":"Diabet Med"},{"issue":"6","key":"2400_CR10","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1210\/er.2018-00174","volume":"40","author":"RA Lal","year":"2019","unstructured":"Lal\u00a0RA, Ekhlaspour\u00a0L, Hood\u00a0K, Buckingham\u00a0B. Realizing a\u00a0closed-loop (artificial pancreas) system for the treatment of type\u00a01 diabetes. Endocr Rev. 2019;40(6):1521\u201346.","journal-title":"Endocr Rev"},{"key":"2400_CR11","unstructured":"Health C for D and R. What is the pancreas? What is an artificial pancreas device system? 2023. https:\/\/www.fda.gov\/medical-devices\/artificial-pancreas-device-system\/what-pancreas-what-artificial-pancreas-device-system. Zugegriffen: 27. M\u00e4rz 2024."},{"issue":"02","key":"2400_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/a-2029-5259","volume":"19","author":"B Gehr","year":"2024","unstructured":"Gehr\u00a0B, G\u00f6lz\u00a0S. Automatische Insulinabgabe-Systeme (\u201eAID-Systeme\u201c). Diabetol Stoffwechs. 2024;19(02):113\u201327.","journal-title":"Diabetol Stoffwechs"},{"issue":"2","key":"2400_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/dia.2018.0384","volume":"21","author":"NC Foster","year":"2019","unstructured":"Foster\u00a0NC, Beck\u00a0RW, Miller\u00a0KM, Clements\u00a0MA, Rickels\u00a0MR, DiMeglio\u00a0LA, et\u00a0al. State of type\u00a01 diabetes management and outcomes from the T1D exchange in 2016\u20132018. Diabetes Technol Ther. 2019;21(2):66\u201372.","journal-title":"Diabetes Technol Ther"},{"key":"2400_CR14","doi-asserted-by":"crossref","unstructured":"Auzanneau M, Eckert AJ, Meyh\u00f6fer SM, Heni M, Gillessen A, Schwettmann L, et\u00a0al. Area deprivation and demographic factors associated with diabetes technology use in adults with type\u00a01 diabetes in Germany. Frontiers in Endocrinology. 2023. https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1191138. Zugegriffen: 6. Aug. 2023.","DOI":"10.3389\/fendo.2023.1191138"},{"issue":"S1","key":"2400_CR15","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1089\/dia.2023.2511","volume":"25","author":"LH Messer","year":"2023","unstructured":"Messer\u00a0LH, Addala\u00a0A, Weinzimer\u00a0SA. Real-world diabetes technology: overcoming barriers and disparities. Diabetes Technol Ther. 2023;25(S1):S176.","journal-title":"Diabetes Technol Ther"},{"key":"2400_CR16","first-page":"193229682211440","volume":"16","author":"RJ Galindo","year":"2022","unstructured":"Galindo\u00a0RJ, Aleppo\u00a0G, Parkin\u00a0CG, Baidal\u00a0DA, Carlson\u00a0AL, Cengiz\u00a0E, et\u00a0al. Increase access, reduce disparities: recommendations for modifying medicaid CGM coverage eligibility criteria. J\u00a0Diabetes Sci Technol. 2022;16:19322968221144052.","journal-title":"J Diabetes Sci Technol"},{"key":"2400_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06049-5","author":"J Jendle","year":"2023","unstructured":"Jendle\u00a0J, Adolfsson\u00a0P, Choudhary\u00a0P, Dovc\u00a0K, Fleming\u00a0A, Klonoff\u00a0DC, et\u00a0al. A\u00a0narrative commentary about interoperability in medical devices and data used in diabetes therapy from an academic EU\/UK\/US perspective. Diabetologia. 2023; https:\/\/doi.org\/10.1007\/s00125-023-06049-5.","journal-title":"Diabetologia"},{"key":"2400_CR18","first-page":"193229682311641","volume":"13","author":"K Braune","year":"2023","unstructured":"Braune\u00a0K, Hussain\u00a0S, Lal\u00a0R. The first regulatory clearance of an open-source automated insulin delivery algorithm. J\u00a0Diabetes Sci Technol. 2023;13:19322968231164166.","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"2400_CR19","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1177\/1932296820932928","volume":"14","author":"ML Litchman","year":"2020","unstructured":"Litchman\u00a0ML, Walker\u00a0HR, Fitzgerald\u00a0C, Gomez Hoyos\u00a0M, Lewis\u00a0D, Gee\u00a0PM. Patient-driven diabetes technologies: sentiment and personas of the #WeAreNotWaiting and #OpenAPS movements. J\u00a0Diabetes Sci Technol. 2020;14(6):990\u20139.","journal-title":"J Diabetes Sci Technol"},{"issue":"4","key":"2400_CR20","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/1932296818808307","volume":"13","author":"D Lewis","year":"2019","unstructured":"Lewis\u00a0D. History and perspective on DIY closed looping. J\u00a0Diabetes Sci Technol. 2019;13(4):790\u20133.","journal-title":"J Diabetes Sci Technol"},{"issue":"5","key":"2400_CR21","doi-asserted-by":"publisher","first-page":"e14750","DOI":"10.1111\/dme.14750","volume":"39","author":"H Crocket","year":"2022","unstructured":"Crocket\u00a0H, Lewis\u00a0DM, Burnside\u00a0M, Faherty\u00a0A, Wheeler\u00a0B, Frewen\u00a0C, et\u00a0al. Learning challenges of healthcare professionals supporting open-source automated insulin delivery. Diabet Med. 2022;39(5):e14750.","journal-title":"Diabet Med"},{"key":"2400_CR22","doi-asserted-by":"crossref","unstructured":"Huhndt A, Chen Y, O\u2019Donnell S, Cooper D, Ballhausen H, Gajewska KA, et\u00a0al. Barriers to Uptake of Open-Source Automated Insulin Delivery Systems: Analysis of Socioeconomic Factors and Perceived Challenges of Caregivers of Children and Adolescents With Type\u00a01 Diabetes From the OPEN Survey. 2022. https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2022.876511. Zugegriffen: 27. Sept. 2022, Frontiers in Clinical Diabetes and Healthcare.","DOI":"10.3389\/fcdhc.2022.876511"},{"issue":"Supplement_1","key":"2400_CR23","doi-asserted-by":"publisher","first-page":"78-LB","DOI":"10.2337\/db19-78-LB","volume":"68","author":"B Cleal","year":"2019","unstructured":"Cleal\u00a0B, Braune\u00a0K, O\u2019Donnell\u00a0S, Hauck\u00a0B, Lewis\u00a0DM, Skinner\u00a0TC, et\u00a0al. 78-LB: detailing the experiences of people with diabetes using do-it-yourself artificial pancreas systems\u2014qualitative analysis of responses to open-ended items in an international survey. Diabetes. 2019;68(Supplement_1):78-LB.","journal-title":"Diabetes"},{"issue":"4","key":"2400_CR24","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1177\/17423953221142341","volume":"19","author":"LH Raimond","year":"2023","unstructured":"Raimond\u00a0LH, O\u2019Donnell\u00a0S, B\u00f8ggild-Damkvist\u00a0T, Filges\u00a0T, Lomborg\u00a0K. Open-source automated insulin delivery systems and formal healthcare: a\u00a0qualitative study of challenges in the interaction between service-users with type\u00a01 diabetes and healthcare professionals. Chronic Illness. 2023;19(4):836\u201347.","journal-title":"Chronic Illness"},{"key":"2400_CR25","first-page":"193229682095772","volume":"1","author":"JA Shepard","year":"2020","unstructured":"Shepard\u00a0JA, Breton\u00a0M, Nimri\u00a0R, Roberts\u00a0JTF, Street\u00a0T, Klonoff\u00a0D, et\u00a0al. User and healthcare professional perspectives on do-it-yourself artificial pancreas systems: a\u00a0need for guidelines. J\u00a0Diabetes Sci Technol. 2020;1:1932296820957728.","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"2400_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S2213-8587(21)00267-9","volume":"10","author":"K Braune","year":"2022","unstructured":"Braune\u00a0K, Lal\u00a0RA, Petru\u017eelkov\u00e1\u00a0L, Scheiner\u00a0G, Winterdijk\u00a0P, Schmidt\u00a0S, et\u00a0al. Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. Lancet Diabetes Endocrinol. 2022;10(1):58\u201374.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2400_CR27","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1177\/1932296819890623","volume":"14","author":"M Burnside","year":"2020","unstructured":"Burnside\u00a0M, Crocket\u00a0H, Mayo\u00a0M, Pickering\u00a0J, Tappe\u00a0A, de Bock\u00a0M. Do-it-yourself automated insulin delivery: a\u00a0leading example of the democratization of medicine. J\u00a0Diabetes Sci Technol. 2020;14(5):878\u201382.","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"2400_CR28","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1177\/1932296819883876","volume":"14","author":"H Crocket","year":"2020","unstructured":"Crocket\u00a0H. Peer mentoring in the do-it-yourself artificial pancreas system community. J\u00a0Diabetes Sci Technol. 2020;14(6):1022\u20137.","journal-title":"J Diabetes Sci Technol"},{"key":"2400_CR29","unstructured":"DIYPS.org. DIYPS.org. DIYPS.org. 2021. https:\/\/diyps.org;. Zugegriffen: 28. M\u00e4rz 2024."},{"key":"2400_CR30","unstructured":"Diabetes Australia. Position Statements. 2019. https:\/\/www.diabetesaustralia.com.au\/position-statements\/. Zugegriffen: 28. M\u00e4rz 2024."},{"key":"2400_CR31","unstructured":"Steno Diabetes Center Copenhagen. Guidelines for the use of unauthorized Do-It-Yourself (DIY) medical technologies for the treatment of diabetes. 2019. https:\/\/www.sdcc.dk\/presse-og-nyheder\/nyheder\/Documents\/SDCC%20guidelines%20for%20DIY%20medical%20systems-english-version-200519.pdf. Zugegriffen: 28. M\u00e4rz 2021."},{"key":"2400_CR32","unstructured":"JDRF. Type\u00a01 Diabetes DIY Technology\u2014JDRF UK Position Statement. 2019. http:\/\/jdrf.org.uk\/wp-content\/uploads\/2019\/02\/JDRF-UK-Position-Statement-.pdf. Zugegriffen: 16. Nov. 2022."},{"key":"2400_CR33","unstructured":"Diabetes UK. Do it yourself (DIY) closed loop for people living with Type\u00a01 diabetes. 2020. https:\/\/www.diabetes.org.uk\/about-us\/about-the-charity\/our-strategy\/position-statements\/do-it-yourself-closed-loop. Zugegriffen: 28. M\u00e4rz 2024."},{"key":"2400_CR34","unstructured":"Tidepool Blog. The Tidepool Period Project \u201cWhy\u201d. https:\/\/www.tidepool.org\/blog\/the-tidepool-period-project-why. Zugegriffen: 16. M\u00e4rz 2023."},{"key":"2400_CR35","unstructured":"Tidepool. Automated insulin dosing. https:\/\/www.tidepool.org\/automated-insulin-dosing. Zugegriffen: 31. M\u00e4rz 2024."},{"key":"2400_CR36","unstructured":"The OPEN Project. Publikationen. https:\/\/open-diabetes.eu\/de\/publikationen\/. Zugegriffen: 14. Nov. 2021."},{"key":"2400_CR37","doi-asserted-by":"crossref","unstructured":"Hussain S, Lal RA, Braune K. Open-source automated insulin delivery in type\u00a01 diabetes\u2014the evidence is out there. Lancet Diabetes Endocrinol. 2022; S2213858722002832.","DOI":"10.1016\/S2213-8587(22)00283-2"},{"issue":"10","key":"2400_CR38","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1056\/NEJMoa2203913","volume":"387","author":"MJ Burnside","year":"2022","unstructured":"Burnside\u00a0MJ, Lewis\u00a0DM, Crocket\u00a0HR, Meier\u00a0RA, Williman\u00a0JA, Sanders\u00a0OJ, et\u00a0al. Open-source automated insulin delivery in type\u00a01 diabetes. N\u00a0Engl J Med. 2022;387(10):869\u201381.","journal-title":"N Engl J Med"},{"issue":"4","key":"2400_CR39","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1089\/dia.2022.0484","volume":"25","author":"MJ Burnside","year":"2023","unstructured":"Burnside\u00a0MJ, Lewis\u00a0DM, Crocket\u00a0HR, Meier\u00a0RA, Williman\u00a0JA, Sanders\u00a0OJ, et\u00a0al. Extended use of an open-source automated insulin delivery system in children and adults with type\u00a01 diabetes: the 24-week continuation phase following the CREATE randomized controlled trial. Diabetes Technol Ther. 2023;25(4):250\u20139.","journal-title":"Diabetes Technol Ther"},{"key":"2400_CR40","first-page":"193229682211141","volume":"1","author":"M M\u00fcller-Korbsch","year":"2022","unstructured":"M\u00fcller-Korbsch\u00a0M, Fr\u00fchwald\u00a0L, Kietaibl\u00a0A. Changes in ambulatory glucose profile in patients with type\u00a01 diabetes mellitus after switching from sensor-augmented insulin pump therapy to a\u00a0do-it-yourself artificial pancreas system: a\u00a0retrospective data analysis of real-world data. J\u00a0Diabetes Sci Technol. 2022;1:19322968221114112.","journal-title":"J Diabetes Sci Technol"},{"key":"2400_CR41","doi-asserted-by":"publisher","first-page":"193229682412301","DOI":"10.1177\/19322968241230106","volume":"16","author":"A Sch\u00fctz","year":"2024","unstructured":"Sch\u00fctz\u00a0A, Rami-Merhar\u00a0B, Sch\u00fctz-Fuhrmann\u00a0I, Blauensteiner\u00a0N, Baumann\u00a0P, P\u00f6ttler\u00a0T, et\u00a0al. Retrospective comparison of commercially available automated insulin delivery with open-source automated insulin delivery systems in type\u00a01 diabetes. J\u00a0Diabetes Sci Technol. 2024;16:19322968241230106.","journal-title":"J Diabetes Sci Technol"},{"key":"2400_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03683-w","author":"Z Landau","year":"2024","unstructured":"Landau\u00a0Z, Lebenthal\u00a0Y, Mazor-Aronovitch\u00a0K, Brener\u00a0A, Levek\u00a0N, Jacobi-Polishook\u00a0T, et\u00a0al. A\u00a0comparison of the usage of an open-source automated insulin delivery system and the MiniMedTM 780\u202fG system in children and adolescents with type\u00a01 diabetes in real-world settings: the AWeSoMe study group. Endocrine. 2024; https:\/\/doi.org\/10.1007\/s12020-024-03683-w.","journal-title":"Endocrine"},{"issue":"5","key":"2400_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jcjd.2023.06.001","volume":"47","author":"A Chambers","year":"2023","unstructured":"Chambers\u00a0A, Mackay\u00a0D, Farnsworth\u00a0K, Morrison\u00a0AE, Witteman\u00a0HO, Senior\u00a0P, et\u00a0al. Do-it-yourself automated insulin delivery: a\u00a0health-care practitioner user\u2019s guide. Can J Diabetes. 2023;47(5):389\u2013397.e8.","journal-title":"Can J Diabetes"},{"issue":"5","key":"2400_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jcjd.2023.05.006","volume":"47","author":"IJ Halperin","year":"2023","unstructured":"Halperin\u00a0IJ, Chambers\u00a0A, Covello\u00a0L, Farnsworth\u00a0K, Morrison\u00a0AE, Schuklenk\u00a0U, et\u00a0al. Do-it-yourself automated insulin delivery: a\u00a0position statement. Can J Diabetes. 2023;47(5):381\u20138.","journal-title":"Can J Diabetes"},{"issue":"8","key":"2400_CR45","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1089\/dia.2019.0105","volume":"21","author":"LH Messer","year":"2019","unstructured":"Messer\u00a0LH, Berget\u00a0C, Forlenza\u00a0GP. A\u00a0clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm. Diabetes Technol Ther. 2019;21(8):462\u20139.","journal-title":"Diabetes Technol Ther"},{"issue":"9","key":"2400_CR46","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s13300-022-01299-9","volume":"13","author":"DM Lewis","year":"2022","unstructured":"Lewis\u00a0DM, Hussain\u00a0S. Practical guidance on open source and commercial automated insulin delivery systems: a\u00a0guide for Healthcare professionals supporting people with insulin-requiring diabetes. Diabetes Ther. 2022;13(9):1683\u201399.","journal-title":"Diabetes Ther"},{"key":"2400_CR47","unstructured":"For Clinicians. A General Introduction and Guide to AAPS\u2014AndroidAPS 3.2\u00a0Dokumentation. https:\/\/androidaps.readthedocs.io\/de\/latest\/Resources\/clinician-guide-to-AndroidAPS.html. Zugegriffen: 28. M\u00e4rz 2024."},{"key":"2400_CR48","unstructured":"Loop and Learn. Resources. https:\/\/www.loopandlearn.org\/resources\/. Zugegriffen: 28. M\u00e4rz 2024."},{"key":"2400_CR49","unstructured":"Lewis D. Understanding Automated Insulin Delivery: A\u00a0basic book for kids, family, and friends of people living with diabetes. 2020. https:\/\/diyps.org\/2020\/08\/05\/understanding-automated-insulin-delivery-a-basic-book-for-kids-family-and-friends-of-people-living-with-diabetes\/. Zugegriffen: 28. M\u00e4rz 2024."},{"key":"2400_CR50","unstructured":"artificial pancreas cl. Automated Insulin Delivery. 2021. https:\/\/www.artificialpancreasbook.com. Zugegriffen: 28. M\u00e4rz 2024."},{"key":"2400_CR51","unstructured":"LoopDocs. https:\/\/loopkit.github.io\/loopdocs\/#what-are-my-next-steps. Zugegriffen: 27. M\u00e4rz 2024."},{"key":"2400_CR52","unstructured":"Welcome to the AAPS documentation\u2014AndroidAPS 3.2\u00a0Dokumentation. https:\/\/androidaps.readthedocs.io\/de\/latest\/index.html. Zugegriffen: 27. M\u00e4rz 2024."},{"key":"2400_CR53","unstructured":"Welcome to OpenAPS\u2019s documentation!\u2014OpenAPS 0.0.0 documentation. https:\/\/openaps.readthedocs.io\/en\/latest\/index.html?highlight=responsibility#welcome-to-openaps-s-documentation. Zugegriffen: 27. M\u00e4rz 2024."},{"key":"2400_CR54","unstructured":"FreeAPSX. The new entry to the DIYAPS world | Diabettech\u2014Diabetes and Technology. 2021. https:\/\/www.diabettech.com\/diyaps\/freeapsx-the-new-entry-to-the-diyaps-world\/. Zugegriffen: 13. Nov. 2022."},{"issue":"8","key":"2400_CR55","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino\u00a0T, Danne\u00a0T, Bergenstal\u00a0RM, Amiel\u00a0SA, Beck\u00a0R, Biester\u00a0T, et\u00a0al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Dia Care. 2019;42(8):1593\u2013603.","journal-title":"Dia Care"},{"issue":"3","key":"2400_CR56","doi-asserted-by":"publisher","first-page":"140","DOI":"10.5114\/pedm.2020.95621","volume":"26","author":"O Kublin","year":"2020","unstructured":"Kublin\u00a0O, St\u0119pie\u0144\u00a0M. The Nightscout system\u2014description of the system and its evaluation in scientific publications. Pediatr Endocrinol Diabetes Metab. 2020;26(3):140\u20133.","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"2400_CR57","unstructured":"Nightscout for clinicians. Nightscout Documentation documentation. https:\/\/nightscout.github.io\/clinicians\/home\/. Zugegriffen: 31. M\u00e4rz 2024."},{"key":"2400_CR58","unstructured":"Loop and Learn. Starting Loop? https:\/\/www.loopandlearn.org\/starting-loop\/. Zugegriffen: 27. M\u00e4rz 2024."},{"issue":"5","key":"2400_CR59","doi-asserted-by":"publisher","first-page":"805","DOI":"10.4158\/EP13099.OR","volume":"19","author":"AP Cemeroglu","year":"2013","unstructured":"Cemeroglu\u00a0AP, Thomas\u00a0JP, Vande Zande\u00a0LT, Nguyen\u00a0NT, Wood\u00a0MA, Kleis\u00a0L, et\u00a0al. Basal and bolus insulin requirements in children, adolescents, and young adults with type\u00a01 diabetes mellitus on continuous subcutaneous insulin infusion (csii): effects of age and puberty. Endocr Pract. 2013;19(5):805\u201311.","journal-title":"Endocr Pract"},{"key":"2400_CR60","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 712-P: International Consensus on the Ethics of Open-Source Automated Insulin Delivery | Diabetes. https:\/\/diabetesjournals.org\/diabetes\/article\/70\/Supplement_1\/712-P\/140802\/712-P-International-Consensus-on-the-Ethics-of. Zugegriffen: 27. Sept. 2022.","DOI":"10.2337\/db21-712-P"},{"key":"2400_CR61","unstructured":"Farnsworth K, Mousavi S, Drescher O, Racine C, Senior P, Witteman H, Diabetes Technology & Therapeutics. WHO IS USING DO-IT-YOURSELF ARTIFICIAL PANCREAS SYSTEMS AND WHY. 2022. https:\/\/scholar.google.com\/citations?view_op=view_citation&hl=en&user=AA1eyxMAAAAJ&citation_for_view=AA1eyxMAAAAJ:9yKSN-GCB0IC. Zugegriffen: 5. Apr. 2024."},{"issue":"5","key":"2400_CR62","doi-asserted-by":"publisher","first-page":"e14839","DOI":"10.1111\/dme.14839","volume":"39","author":"SF Dinneen","year":"2022","unstructured":"Dinneen\u00a0SF, McMorrow\u00a0L. Re-framing type\u00a01 diabetes care through open-source automated insulin delivery: \u2018The (expert) patient will see you now, doctor. Diabet Med. 2022;39(5):e14839.","journal-title":"Diabet Med"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02400-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T18:07:51Z","timestamp":1725300471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02400-x"}},"subtitle":["Technologieausschuss der \u00d6sterreichischen Diabetes Gesellschaft","Technology Committee of the Austrian Diabetes Association"],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":62,"journal-issue":{"issue":"S9","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2400"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02400-x","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"1 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.-T.\u00a0Kietaibl, L.\u00a0Fr\u00fchwald, M.\u00a0Resl, M.\u00a0Eichner und H.\u00a0Stingl geben an, dass kein Interessenkonflikt besteht. B.\u00a0Rami-Merhar: Advisory boards or speakers honorary in the last 3\u00a0years: Abbott, Medtronic, Sanofi, Eli Lilly, Insulet, Dexcom, Novo Nordisk, Ypsomed. C.\u00a0Schelkshorn hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Novo Nordisk, Lilly Austria, B\u00f6hringer Ingelheim, AstraZeneca, Abbott Diabetes, Sanofi, Daiichi Sankyo. E.\u00a0Fr\u00f6hlich-Reiterer hat in den letzten 36\u00a0Monaten von folgenden Firmen Vortragshonorare, Forschungsgelder und Honorare f\u00fcr Beratungst\u00e4tigkeit erhalten: Medtronic, Eli Lilly, Sanofi und Merck, Sandoz. G.\u00a0K\u00f6hler hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi Aventis, Viatris. G.\u00a0Rega-Kaun hat von folgenden Unternehmen Kongressunterst\u00fctzungen und\/oder Honorare erhalten: Abbott, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi. I.\u00a0Sch\u00fctz-Fuhrmann hat von folgenden Unternehmen Honorare erhalten: Abbott, Med Trust, Medtronic, Dexcom. J.K.\u00a0Mader ist in den Advisory Boards von Abbott Diabetes Care, Becton Dickinson\/Embecta, Biomea Fusion, Eli Lilly, Medtronic, Novo Nordisk, Pharmasens, Roche Diabetes Care, Sanofi und Viatris. Sie erhielt Sprecherhonorare von Abbott Diabetes Care, A.\u00a0Menarini Diagnostics, Becton-Dickinson\/Embecta, Eli Lilly, Med Trust, Novo Nordisk, Roche Diabetes Care, Sanofi und Ypsomed. Sie ist Gesellschafterin von decide Clinical Software GmbH und elyte Diagnostics. L.\u00a0Bozkurt hat in den letzten 36\u00a0Monaten von folgenden Firmen Honorare erhalten: Medtronic, Sanofi, Novo Nordisk. L.\u00a0Stechemesser hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Med Trust, MSD, Mylan, Novartis, Novo Nordisk, Roche Diabetes Care, Sanofi Aventis. M.\u00a0Riedl hat Unterst\u00fctzungen der Firma Novo und B\u00f6hringer f\u00fcr Kongressteilnahme erhalten. M.\u00a0Tauschmann hat in den letzten 36\u00a0Monaten von folgenden Firmen Vortragshonorare und Honorare f\u00fcr Beratungst\u00e4tigkeit erhalten: Abbott, Eli Lilly, Medtronic, Sanofi und Ypsomed. R.\u00a0Weitgasser hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott Diabetes Care, Eli Lilly, Medtronic, Med Trust, Novo Nordisk, Roche Diabetes Care. S.E.\u00a0Hofer hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Sanofi, Eli Lilly, Medtronic, Ypsomed, Insulet, Dexcom. S.\u00a0Zlamal-Fortunat war als Vortragende f\u00fcr zahlreiche Pharmafirmen in den letzten 3\u00a0Jahren t\u00e4tig: Med Trust, Medtronic, AstraZeneca, Novartis, Novo Nordisk, Eli Lilly, B\u00f6hringer Ingelheim, Daiichi Sankyo und Sanofi. T.\u00a0H\u00f6rtenhuber hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Medtronic, Sanofi, Merck, Lilly. Y.\u00a0Winhofer hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott, Eli Lilly, Medtronic, Novo Nordisk, Sanofi Aventis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}